Bal Pharma Limited (BOM:524824)
India · Delayed Price · Currency is INR 75.54
+1.22 (1.64%)
At close: Feb 13, 2026
Bal Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 72.15 | 73.92 | 25.72 | 56.12 | 47.42 |
Depreciation & Amortization | 71.06 | 77.77 | 72.11 | 78.52 | 83.33 |
Other Amortization | 26.65 | 22.95 | 19.18 | 11.88 | 11.88 |
Loss (Gain) From Sale of Assets | - | -0.83 | -0.3 | -12.34 | -0.21 |
Loss (Gain) From Sale of Investments | -0 | -11.8 | - | -0.06 | - |
Provision & Write-off of Bad Debts | - | 1.93 | 1.82 | 1.59 | 2.12 |
Other Operating Activities | 108.18 | 104.54 | 141.36 | 115.64 | 106.8 |
Change in Accounts Receivable | 71.49 | -149.54 | -318.93 | -96.68 | -185 |
Change in Inventory | -152.11 | 101.94 | -236.09 | -140.1 | 73.26 |
Change in Accounts Payable | 41.67 | -5.95 | 271.73 | 205.94 | 89.81 |
Change in Other Net Operating Assets | -35.94 | 13.13 | 8.04 | 47.46 | -6.06 |
Operating Cash Flow | 203.15 | 228.06 | -15.37 | 267.96 | 223.35 |
Operating Cash Flow Growth | -10.92% | - | - | 19.97% | -3.91% |
Capital Expenditures | -187.87 | -109.8 | -146.45 | -84.69 | -33.64 |
Sale of Property, Plant & Equipment | - | 0.12 | - | - | - |
Cash Acquisitions | - | - | - | - | -9.79 |
Investment in Securities | 31.33 | -86.11 | -8.1 | -11.94 | -14.65 |
Other Investing Activities | 7.37 | 6.89 | -67.27 | 1.79 | 2.74 |
Investing Cash Flow | -149.17 | -188.91 | -221.82 | -94.85 | -55.35 |
Short-Term Debt Issued | 157.3 | 103.61 | 237.15 | - | - |
Long-Term Debt Issued | - | 58.26 | 117.02 | 30.81 | - |
Total Debt Issued | 157.3 | 161.88 | 354.17 | 30.81 | - |
Short-Term Debt Repaid | - | - | - | -93.3 | -92.59 |
Long-Term Debt Repaid | -49.49 | - | - | - | -36.64 |
Total Debt Repaid | -49.49 | - | - | -93.3 | -129.23 |
Net Debt Issued (Repaid) | 107.81 | 161.88 | 354.17 | -62.49 | -129.23 |
Issuance of Common Stock | 8.07 | 12.28 | 43.75 | - | 32.5 |
Common Dividends Paid | -19.11 | -15.69 | -15.57 | -14.82 | - |
Other Financing Activities | -175.2 | -170.53 | -141.41 | -94.91 | -69.6 |
Financing Cash Flow | -78.42 | -12.06 | 240.94 | -172.22 | -166.32 |
Foreign Exchange Rate Adjustments | - | - | - | - | -0.04 |
Miscellaneous Cash Flow Adjustments | 0 | - | - | - | - |
Net Cash Flow | -24.44 | 27.09 | 3.74 | 0.89 | 1.65 |
Free Cash Flow | 15.28 | 118.26 | -161.83 | 183.26 | 189.71 |
Free Cash Flow Growth | -87.08% | - | - | -3.40% | 4.35% |
Free Cash Flow Margin | 0.50% | 3.49% | -5.32% | 6.52% | 7.57% |
Free Cash Flow Per Share | 0.96 | 7.51 | -10.31 | 12.36 | 13.36 |
Cash Interest Paid | 168.54 | 163.26 | 136.83 | 104.04 | 116.06 |
Cash Income Tax Paid | 20.77 | 45.43 | 5.04 | 12.02 | 4.03 |
Levered Free Cash Flow | -144.66 | 15.36 | -234.05 | 92.28 | 64.91 |
Unlevered Free Cash Flow | -53.79 | 96.01 | -168.45 | 147.75 | 130.78 |
Change in Working Capital | -74.89 | -40.43 | -275.25 | 16.61 | -27.99 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.